

**Brilliant Violet 785™ anti-human CD16**

**Catalog # / Size:** 2110225 / 25 tests  
2110230 / 100 tests

**Clone:** 3G8

**Isotype:** Mouse IgG1, κ

**Immunogen:** Human PMN cells


**Reactivity:** Human

**Preparation:** The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 785™ under optimal conditions. The solution is free of unconjugated Brilliant Violet 785™ and unconjugated antibody.

**Formulation:** Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).

**Workshop Number:** V NK80

**Concentration:** Lot-specific




Human peripheral blood lymphocytes were stained with CD56 APC and CD16 (clone 3G8) Brilliant Violet 785™ (top) or mouse IgG1, κ Brilliant Violet 785™ isotype control (bottom).

**Applications:**

**Applications:** Flow Cytometry

**Recommended Usage:** Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤5 microL per million cells or 5 microL per 100 microL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.



Brilliant Violet 785™ excites at 405 nm and emits at 785 nm. The bandpass filter 780/60 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. **Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel.** Refer to your instrument manual or manufacturer for support. Brilliant Violet 785™ is a trademark of Sirigen Group Ltd.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use

the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.

**Application Notes:** The 3G8 antibody blocks neutrophil phagocytosis and stimulates NK cell proliferation. Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen tissue sections<sup>6</sup>, immunoprecipitation<sup>3</sup>, stimulation of NK cell proliferation<sup>4</sup>, blocking of phagocytosis<sup>5</sup>, and blocking of immunoglobulin binding to FcγRIII<sup>7,8</sup>. The LEAF™ purified antibody (Endotoxin <0.1 EU/μg, Azide-Free, 0.2 μm filtered) is recommended for functional assays (Cat. No. 302014). For highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 302050) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/microg).

**Application References:**

1. Knapp W, *et al.* Eds. 1989. Leucocyte Typing IV. Oxford University Press. New York.
2. Schlossman S, *et al.* Eds. 1995. Leucocyte Typing V. Oxford University Press. New York.
3. Edberg J, *et al.* 1997. *J. Immunol.* 159:3849. (IP)
4. Hoshino S, *et al.* 1991. *Blood* 78:3232. (Stim)
5. Tamm A, *et al.* 1996. *Immunol.* 157:1576. (Block)
6. Da Silva DM, *et al.* 2001. *Int. Immunol.* 13:633. (IHC)
7. Holl V, *et al.* 2004. *J. Immunol.* 173:6274. (Block)
8. Hober D, *et al.* 2002. *J. Gen. Virol.* 83:2169. (Block)
9. Brainard DM, *et al.* 2009. *J. Virol.* 83:7305. [PubMed](#)
10. Smed-Sørensen A, *et al.* 2008. *Blood* 111:5037. (Block) [PubMed](#)
11. Timmerman KL, *et al.* 2008. *J. Leukoc. Biol.* 84:1271. (FC) [PubMed](#)
12. Yoshino N, *et al.* 2000. *Exp. Anim. (Tokyo)* 49:97. (FC)
13. Rout N, *et al.* 2010. *PLoS One* 5:e9787. (FC)
14. Kim WK, *et al.* 2006. *Am. J. Pathol.* 168:822. (FC)
15. Boltz A, *et al.* 2011. *J. Biol Chem.* 286:21896. [PubMed](#)
16. Wu Z, *et al.* 2013. *J. Virol.* 87:7717. [PubMed](#)
17. Marguardt N, *et al.* 2015. *J Immunol.* 194:2467. [PubMed](#)

---

**Description:** CD16 is known as low affinity IgG receptor III (FcγRIII). It is expressed as two distinct forms (CD16a and CD16b). CD16a (FcγRIIIA) is a 50-65 kD polypeptide-anchored transmembrane protein. It is expressed on the surface of NK cells, activated monocytes, macrophages, and placental trophoblasts in humans. CD16b (FcγRIIIB) is a 48 kD glycosylphosphatidylinositol (GPI)-anchored protein. Its extracellular domain is over 95% homologous to that of CD16a, and it is expressed specifically on neutrophils. CD16 binds aggregated IgG or IgG-antigen complex which functions in NK cell activation, phagocytosis, and antibody-dependent cell-mediated cytotoxicity (ADCC).

**Antigen References:**

1. Fleit H, *et al.* 1982. *P. Natl. Acad. Sci. USA* 79:3275.
2. Stroncek D, *et al.* 1991. *Blood* 77:1572.
3. Wirthmueller U, *et al.* 1992. *J. Exp. Med.* 175:1381.